ArticleDiabetes, obesity & metabolism2021
The burden of poor glycaemic control in people with newly diagnosed type 2 diabetes in Sweden: A health economic modelling analysis based on nationwide data.
Article in Diabetes, obesity & metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Modelling the Clinical and Complication-Related Economic Burden of Therapeutic Inertia in People With Type 2 Diabetes in China.Diabetes, obesity & metabolism · 2026Article
- Cost-Effectiveness of Automated Insulin Delivery Systems in Paediatrics, T1D and T2D Adults Across Four Nordic Countries.Diabetes, obesity & metabolism · 2026Article
- The healthcare and economic burden associated with inadequate risk factor control for type 2 diabetes in Hong Kong: A population-based modelling study.Diabetes, obesity & metabolism · 2025Article
- Glycemic control and associated factors among type 2 diabetes patients attending at Dessie comprehensive specialized hospital outpatient department.Scientific reports · 2025Article
- Poor glycemic control impairs recovery from central retinal vein occlusion.Molecular vision · 2025Article
- Estimating the societal cost of type 2 diabetes in Malmö, Sweden: a register-based cost analysis.Frontiers in clinical diabetes and healthcare · 2025Article
- Modeling the Clinical and Economic Burden of Therapeutic Inertia in People with Type 2 Diabetes in Saudi Arabia.Advances in therapy · 2024Article
- PIONEER REAL Sweden: A Multicentre, Prospective, Real-World Observational Study of Oral Semaglutide Use in Adults with Type 2 Diabetes in Swedish Clinical Practice.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Burden of Illness of Type 2 Diabetes Mellitus in the Kingdom of Saudi Arabia: A Five-Year Longitudinal Study.Advances in therapy · 2024Article
- Disease and Economic Burden of Poor Metabolic and Weight Control in Type 2 Diabetes in Spain: A Systematic Literature Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Review
- Socioeconomic factors associated with poor medication adherence in patients with type 2 diabetes.European journal of clinical pharmacology · 2024Article
- Prediction of complications in health economic models of type 2 diabetes: a review of methods used.Acta diabetologica · 2023Review
- Evaluating the Clinical and Economic Outcomes Associated with Poor Glycemic Control in People with Type 1 Diabetes in the Netherlands.ClinicoEconomics and outcomes research : CEOR · 2023Article
- Assessing the Effectiveness of Type 2 Diabetes Screening in the Republic of Uzbekistan.International journal of endocrinology and metabolism · 2022Article
- The public economic burden of suboptimal type 2 diabetes control upon taxpayers in Sweden: Looking beyond health costs.Diabetes, obesity & metabolism · 2022Article
- The burden of poor glycaemic control in people with newly diagnosed type 2 diabetes in Sweden: A health economic modelling analysis based on nationwide data.Diabetes, obesity & metabolism · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the economic and clinical burden associated with poor glycaemic control in Sweden, in people with type 2 diabetes (T2D) initiating first-line glucose-lowering therapy. MATERIALS AND
methodsPopulation data were obtained from Swedish national registers. Immediate glycaemic control was compared with delays in achieving control of 1 and 3 years, with outcomes projected over 3, 10 and 50 years in the validated IQVIA CORE Diabetes Model. Glycaemic control was defined as glycated haemoglobin (HbA1c) targets of 52, 48 and 42 mmol/mol, as recommended in Swedish guidelines, according to age and disease duration. Costs (expressed in 2019 Swedish krona [SEK]) were accounted from a Swedish societal perspective.
resultsImmediate glycaemic control was associated with population-level cost savings of up to SEK 279 million and SEK 673 million versus delays of 1 and 3 years, respectively, as well as small population-level life expectancy benefits of up to 1305 and 2590 life years gained. Reduced levels of burden were a result of lower incidence and delayed time to onset of diabetes-related complications.
conclusionsEven in people with T2D initiating first-line glucose-lowering therapy, the economic burden of poor glycaemic control in Sweden is substantial, but could be reduced by early and effective treatment to achieve glycaemic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.